New Era of Drug Price Competition: EP2006 Recommendation Sets Stage
FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously to recommend approval of EP2006 as the first biosimilar drug available in the United States. ODAC found EP2006 to be highly similar to the biologics medication filgrastrim (Neupogen).